In recent years, Britannia Pharmaceuticals has undergone rapid and significant geographical expansion, managed from our global headquarters in the UK.

80% of our business now sits outside the UK and we continue to strive to make our therapies and expertise available to patients wherever they are in the world.

As of 2018, we are currently active in over 30 markets, including the US, EU and Japan. We work with an ever-growing network of affiliates and partners to optimise our global reach.

To make our expansion sustainable, we continue to develop and replicate our support network in new markets, training nurses and educating local healthcare teams on evolving technologies and specialist care.

We are also active at global neurology conferences and symposia to help advance international understanding of our disease areas and build awareness around our therapies.